Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The future--can we learn from the past?

W A Craig1

  • 1William S. Middleton Memorial VA Hospital, Madison, WI 53705, USA.

Diagnostic Microbiology and Infectious Disease
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Antimicrobial agents and chemotherapy·2014
Same author

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Antimicrobial agents and chemotherapy·2013
Same author

In vivo pharmacodynamics of new lipopeptide MX-2401.

Antimicrobial agents and chemotherapy·2010
Same author

In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Antimicrobial agents and chemotherapy·2008
Same author

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Antimicrobial agents and chemotherapy·2006
Same author

Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.

Antimicrobial agents and chemotherapy·2005

Antibiotic resistance is a growing problem, partly due to incorrect prescribing. Optimizing antibiotic use by monitoring time above the minimum inhibitory concentration (MIC) can improve treatment effectiveness and slow resistance.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Antibiotic resistance in bacterial pathogens is a significant global health threat.
  • Inappropriate antibiotic prescribing contributes to the rise of untreatable infections.
  • Predicting antibiotic efficacy is crucial for effective treatment and resistance management.

Purpose of the Study:

  • To evaluate the clinical value of 'time above minimum inhibitory concentration' (T>MIC) as a predictor of antibiotic efficacy.
  • To explore strategies for optimizing antibiotic use in community-acquired infections.
  • To investigate methods for delaying the development of antibiotic resistance.

Main Methods:

  • Review of animal studies and clinical trials investigating pharmacokinetic/pharmacodynamic (PK/PD) parameters.

Related Experiment Videos

  • Analysis of data correlating T>MIC with treatment outcomes for beta-lactam antibiotics.
  • Assessment of the potential impact of T>MIC-guided therapy on antibiotic resistance.

    • Main Results:

    • Animal studies indicate that maintaining antibiotic levels above the MIC for 40-50% of the dosing interval predicts efficacy for beta-lactam antibiotics.
    • Emerging clinical data support the value of T>MIC as a reliable indicator of treatment success.
    • Optimizing T>MIC can enhance the effectiveness of current antibiotic regimens.

    Conclusions:

    • Clinical application of T>MIC monitoring can improve patient outcomes for bacterial infections.
    • Effective use of existing antibiotics, guided by T>MIC, may help mitigate the development of antibiotic resistance.
    • This approach provides a critical window for research and development of novel antimicrobial agents.